The FDA rejected ITM's radiopharmaceutical for neuroendocrine tumors because of manufacturing issues, delaying a potential challenger to Novartis’ Lutathera.
The FDA rejected ITM Isotope Technologies Munich’s radiopharmaceutical agent for neuroendocrine tumors because of manufacturing issues, delaying a potential challenger to Novartis’ approved drug Lutathera.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
Pharmalittle: We're reading about an FDA rejection, 340B court battles, and more
Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path
The promise of radiopharmaceuticals smacks into safety concerns
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle
The FDA has denied ITM Isotopes Techn | The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of…
The FDA has rejected a radiopharmaceutical therapy due to manufacturing issues, halting what would have been a competitor for…
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with…
The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for…
The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key…
Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to secure a…
